Fate Therapeutics (NASDAQ: FATE) Price Target Lowered to $71.00 at Piper Sandler
Fate Therapeutics (NASDAQ:FATE – Get Rating) had its price target lowered by analysts at Piper Sandler from $113.00 to $71.00 in a research report released on Monday, reports The Fly. Piper Sandler’s price target suggests a potential upside of 207.36% from the company’s previous close.
FATE has been the subject of several other research reports. Truist Financial lowered its price target on Fate Therapeutics from $125.00 to $75.00 in a Wednesday, April 13 research report. StockNews.com upgraded Fate Therapeutics to a “sell” rating in a Thursday, March 24 research note. Wedbush raised its price target on Fate Therapeutics from $74.00 to $77.00 and gave the company an “outperform” rating in a Tuesday, March 1 research note. Cantor Fitzgerald reiterated an “overweight” rating on Fate Therapeutics shares in a Friday, April 1 research note. Finally, HC Wainwright reduced its price target on Fate Therapeutics from $122.00 to $115.00 and set a “buy” rating for the company in a Friday, March 4 research note. One financial analyst gave the stock a sell rating, two gave the stock a hold rating and seven gave the stock a buy rating. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $85.60.
Shares of Fate Therapeutics opened at $23.10 on Monday. Fate Therapeutics has a 52-week minimum of $20.49 and a 52-week maximum of $97.43. The stock has a market capitalization of $2.23 billion, a price-earnings ratio of -9.51 and a beta of 1.69. The company’s 50-day moving average price is $33.20 and its 200-day moving average price is $41.82.
Fate Therapeutics (NASDAQ:FATE – Get Rating) last reported quarterly results on Wednesday, May 4. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. The company posted revenue of $18.40 million for the quarter, compared to $9.01 million expected by analysts. Fate Therapeutics had a negative net margin of 368.76% and a negative return on equity of 34.89%. The company’s revenue for the quarter increased by 65.2% compared to the same quarter last year. In the same quarter a year earlier, the company posted ($0.48) earnings per share. Analysts expect Fate Therapeutics to post earnings per share of -3.37 for the current year.
In other Fate Therapeutics news, General Counsel Cindy Tahl sold 25,000 shares of the company in a trade on Friday, April 1. The stock was sold at an average price of $38.85, for a total transaction of $971,250.00. Following the transaction, the General Counsel now owns 189,151 shares of the company, valued at $7,348,516.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. Additionally, insider Yu-Waye Chu sold 4,062 shares of Fate Therapeutics in a trade on Tuesday, April 19. The shares were sold at an average price of $35.37, for a total value of $143,672.94. Following the completion of the sale, the insider now owns 151,033 shares of the company, valued at approximately $5,342,037.21. The disclosure of this sale can be found here. Insiders sold 90,624 shares of the company worth $3,270,224 in the past ninety days. Company insiders own 18.58% of the company’s shares.
A number of institutional investors and hedge funds have recently increased or reduced their stakes in the stock. ARK Investment Management LLC increased its position in Fate Therapeutics shares by 6.6% during the 1st quarter. ARK Investment Management LLC now owns 10,988,182 shares of the biopharmaceutical company worth $426,012,000 after acquiring an additional 676,015 shares in the last quarter. BlackRock Inc. increased its stake in shares of Fate Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 7,105,671 shares of the biopharmaceutical company worth $275,487,000 after buying an additional 45,119 shares last quarter. Capital World Investors increased its equity stake in Fate Therapeutics by 39.9% during the 1st quarter. Capital World Investors now owns 4,559,673 shares of the biopharmaceutical company worth $176,779,000 after buying an additional 1,300,640 shares last quarter. Bellevue Group AG increased its stake in shares of Fate Therapeutics by 16.6% during the 4th quarter. Bellevue Group AG now owns 3,775,736 shares of the biopharmaceutical company worth $220,918,000 after purchasing an additional 537,700 shares last quarter. Finally, State Street Corp increased its stake in Fate Therapeutics by 27.7% in the 1st quarter. State Street Corp now owns 3,472,432 shares of the biopharmaceutical company valued at $134,626,000 after buying an additional 753,639 shares last quarter.
About Fate Therapeutics (Get an assessment)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK and T cell immuno-oncology programs in development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma and advanced solid tumors; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematological malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Fate Therapeutics right now?
Before you consider Fate Therapeutics, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Fate Therapeutics didn’t make the list.
Although Fate Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here